I-Mab, a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies ...
Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adultsCosibelimab PDUFA goal date of December 28 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback